title: Nail toxicities induced by systemic anticancer treatments.
abstract: Patients treated with systemic anticancer drugs often show changes to their nails, which are usually well tolerated and disappear on cessation of treatment. However, some nail toxicities can cause pain and functional impairment and thus substantially affect a patient's quality of life, especially if they are given taxanes or EGFR inhibitors. These nail toxicities can affect both the nail plate and bed, and might present as melanonychia, leukonychia, onycholysis, onychomadesis, Beau's lines, or onychorrhexis, as frequently noted with conventional chemotherapies. Additionally, the periungual area (perionychium) of the nail might be affected by paronychia or pyogenic granuloma, especially in patients treated with drugs targeting EGFR or MEK. We review the nail changes induced by conventional chemotherapies and those associated with the use of targeted anticancer drugs and discuss preventive or curative options.
authors.affiliation: Gustave Roussy, Département de Médicine Oncologique, Service de Dermatologie, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicetre, France. Electronic address: caroline.robert@gustaveroussy.fr.
authors.forename: Caroline
authors.initials: C
authors.lastname: Robert
authors.affiliation: Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Sibaud
authors.affiliation: Gustave Roussy, Département de Médicine Oncologique, Service de Dermatologie, Villejuif, France.
authors.forename: Christina
authors.initials: C
authors.lastname: Mateus
authors.affiliation: Department of Research and Innovation, L'Oreal, Paris, France.
authors.forename: Michèle
authors.initials: M
authors.lastname: Verschoore
authors.affiliation: Département Interdisciplinaire de Soins de Support en Oncologie, Villejuif, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Charles
authors.affiliation: Département de Biostatistiques, Villejuif, France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Lanoy
authors.affiliation: Gustave Roussy, Département de Médicine Oncologique, Service de Dermatologie, Villejuif, France.
authors.forename: Robert
authors.initials: R
authors.lastname: Baran
mesh_terms: D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009260:Nail Diseases / Q000139:chemically induced / Q000473:pathology*; D009262:Nails / Q000187:drug effects / Q000473:pathology*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D043823:Taxoids / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D043823:Taxoids; C512478:EGFR protein, human; D066246:ErbB Receptors